Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approves New Plaque Psoriasis Drug
FDA news release; 2017 Feb 15
The US Food and Drug Administration has approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is marketed by Bridgewater, NJ-based Valeant Pharmaceuticals.
Indications: Siliq is intended for adult patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.
Dosage/administration: Siliq is administered (210 mg) by subcutaneous injection at weeks 0, 1, and 2, followed by 210 mg every 2 weeks.
Adverse effects: The most common adverse reactions were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections
US Food and Drug Administration. FDA approves new psoriasis drug. FDA Web site. February 15, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm541981.htm. Accessed February 22, 2017.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Jeuveau for Glabellar Lines, FirstWord Pharma news release; 2019 Feb 1
FDA Approves Hyrimoz for Plaque Psoriasis, Sandoz news release; 2018 Oct 31
FDA Approves Seysara for Severe Acne Vulgaris, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
FDA Approves Nuzyra for Acute Skin Infections, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8